depemokimab

GSK Secures Landmark Exdensur (Depemokimab) China Approval for Severe Asthma

By Regulatory Intelligence Desk
11 April 2026

GSK has reached a major milestone with the NMPA’s Exdensur depemokimab China approval. This ultra-long-acting biologic offers a breakthrough for severe asthma patients, requiring only two doses per year to maintain symptom control.

Regulatory Approval Healthcare & Pharmaceuticals News Regulatory

Exdensur (depemokimab) China approval: A Paradigm Shift in Severe Asthma Treatment

By Regulatory Intelligence Desk
31 March 2026

GSK has secured the Exdensur depemokimab China approval from the NMPA, introducing the first respiratory biologic with a twice-yearly dosing regimen for patients with severe eosinophilic asthma.

Tag: depemokimab

GSK Secures Landmark Exdensur (Depemokimab) China Approval for Severe Asthma

Exdensur (depemokimab) China approval: A Paradigm Shift in Severe Asthma Treatment

Areas Covered

Discover More

Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN

LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C

GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline

Johnson & Johnson Q2 2026 Analysis: Company Reports $25.3 Billion in Sales, Raises Full-Year Outlook

Merck’s Erbitux BRAF V600E mCRC Regimen Gets EU Approval for First-Line Treatment

AstraZeneca Zegfrovy Deal: AstraZeneca Licenses Dizal’s Oral EGFR Inhibitor for Lung Cancer in Up to $1.5 Billion Agreement